David K Grandy1, Gregory M Miller2, Jun-Xu Li3. 1. Department of Physiology and Pharmacology, School of Medicine, Oregon Health and Science University, Portland, OR, USA. 2. Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA, USA. 3. Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA. Electronic address: junxuli@buffalo.edu.
Abstract
BACKGROUND: In keeping with the free-thinking tradition San Antonians are known for, the Scientific Program Committee of the Behavior, Biology and Chemistry: Translational Research in Addiction Conference chose trace amine-associated receptor 1 (TAAR1) as the focus of the plenary symposium for its 7th annual meeting held at the University of Texas Health Science Center at San Antonio on March 14 and 15, 2015. The timing of the meeting's plenary session on TAAR1 coincided with the Ides of March, an apt concurrence given the long association of this date with the overthrow of the status quo. And whether aware of the coincidence or not, those in attendance witnessed the plunging of the metaphorical dagger into the heart of the dopamine (DA) transporter (DAT)-centric view of psychostimulant action. METHODS: The symposium's four plenary presentations focused on the molecular and cellular biology, genetics, medicinal chemistry and behavioral pharmacology of the TAAR1 system and the experimental use of newly developed selective TAAR1 ligands. RESULTS: The consensus was that TAAR1 is a DA and methamphetamine receptor, interacts with DAT and DA D2 receptors, and is essential in modulating addiction-related effects of psychostimulants. CONCLUSIONS: Collectively the findings presented during the symposium constitute a significant challenge to the current view that psychostimulants such as methamphetamine and amphetamine solely target DAT to interfere with normal DA signaling and provide a novel conceptual framework from which a more complete understanding of the molecular mechanisms underlying the actions of DA and METH is likely to emerge.
BACKGROUND: In keeping with the free-thinking tradition San Antonians are known for, the Scientific Program Committee of the Behavior, Biology and Chemistry: Translational Research in Addiction Conference chose trace amine-associated receptor 1 (TAAR1) as the focus of the plenary symposium for its 7th annual meeting held at the University of Texas Health Science Center at San Antonio on March 14 and 15, 2015. The timing of the meeting's plenary session on TAAR1 coincided with the Ides of March, an apt concurrence given the long association of this date with the overthrow of the status quo. And whether aware of the coincidence or not, those in attendance witnessed the plunging of the metaphorical dagger into the heart of the dopamine (DA) transporter (DAT)-centric view of psychostimulant action. METHODS: The symposium's four plenary presentations focused on the molecular and cellular biology, genetics, medicinal chemistry and behavioral pharmacology of the TAAR1 system and the experimental use of newly developed selective TAAR1 ligands. RESULTS: The consensus was that TAAR1 is a DA and methamphetamine receptor, interacts with DAT and DA D2 receptors, and is essential in modulating addiction-related effects of psychostimulants. CONCLUSIONS: Collectively the findings presented during the symposium constitute a significant challenge to the current view that psychostimulants such as methamphetamine and amphetamine solely target DAT to interfere with normal DA signaling and provide a novel conceptual framework from which a more complete understanding of the molecular mechanisms underlying the actions of DA and METH is likely to emerge.
Authors: Annette E Fleckenstein; Trent J Volz; Evan L Riddle; James W Gibb; Glen R Hanson Journal: Annu Rev Pharmacol Toxicol Date: 2007 Impact factor: 13.820
Authors: J R Bunzow; M S Sonders; S Arttamangkul; L M Harrison; G Zhang; D I Quigley; T Darland; K L Suchland; S Pasumamula; J L Kennedy; S B Olson; R E Magenis; S G Amara; D K Grandy Journal: Mol Pharmacol Date: 2001-12 Impact factor: 4.436
Authors: David B Wainscott; Sheila P Little; Tinggui Yin; Yuan Tu; Vincent P Rocco; John X He; David L Nelson Journal: J Pharmacol Exp Ther Date: 2006-10-12 Impact factor: 4.030
Authors: Zhihua Xie; Susan V Westmoreland; Mary E Bahn; Guo-Lin Chen; Hong Yang; Eric J Vallender; Wei-Dong Yao; Bertha K Madras; Gregory M Miller Journal: J Pharmacol Exp Ther Date: 2007-01-18 Impact factor: 4.030
Authors: Evgeny A Budygin; Mark S Brodie; Tatyana D Sotnikova; Yolanda Mateo; Carrie E John; Michel Cyr; Raul R Gainetdinov; Sara R Jones Journal: Proc Natl Acad Sci U S A Date: 2004-05-10 Impact factor: 11.205
Authors: Kenneth J Broadley; M Akhtar Anwar; Amy A Herbert; Martina Fehler; Elen M Jones; Wyn E Davies; Emma J Kidd; William R Ford Journal: Br J Nutr Date: 2008-11-19 Impact factor: 3.718
Authors: Catherine F Moore; Julia I Panciera; Valentina Sabino; Pietro Cottone Journal: Philos Trans R Soc Lond B Biol Sci Date: 2018-03-19 Impact factor: 6.237
Authors: Jian-Feng Liu; Robert Seaman; Justin N Siemian; Rohan Bhimani; Bernard Johnson; Yanan Zhang; Qing Zhu; Marius C Hoener; Jinwoo Park; David M Dietz; Jun-Xu Li Journal: Neuropsychopharmacology Date: 2018-02-05 Impact factor: 7.853
Authors: Antonio Ferragud; Adam D Howell; Catherine F Moore; Tina L Ta; Marius C Hoener; Valentina Sabino; Pietro Cottone Journal: Neuropsychopharmacology Date: 2016-10-06 Impact factor: 7.853
Authors: Olga N Kislitsina; Jonathan D Rich; Jane E Wilcox; Duc T Pham; Andrei Churyla; Esther B Vorovich; Kambiz Ghafourian; Clyde W Yancy Journal: Curr Cardiol Rev Date: 2019